Article
Gastroenterology & Hepatology
Qinchuan Wu, Caixu Pan, Yuan Zhou, Shuai Wang, Liting Xie, Wuhua Zhou, Limin Ding, Tianchi Chen, Junjie Qian, Rong Su, Xingxing Gao, Zhibin Mei, Yiting Qiao, Shengyong Yin, Yi Wu, Jieyi Wang, Lin Zhou, Shusen Zheng
Summary: This study found that PD-1 blockade potentially increases the accumulation of tumor CD4+ regulatory T cells (Tregs), mainly in lymphoid tissues rather than in the tumor. The study also discovered that neuropilin-1 (Nrp-1) supports Tregs migration behavior, and targeting Nrp-1 and 4-1BB can improve the HCC microenvironment and enhance the anti-tumor effect.
Article
Immunology
Arwa Ali, Menghan Gao, Alexandros Iskantar, Hai Wang, Alex Karlsson-Parra, Di Yu, Chuan Jin
Summary: This study evaluated the combination therapy of intratumoral administration of AlloDCs with systemic a4-1BB treatment and found that it significantly enhanced the anti-tumor effects in murine colon carcinoma and melanoma models. The combination treatment improved the tumor microenvironment, increased infiltration of activated immune cells, and led to a less immunosuppressive tumor microenvironment. These findings suggest the potential of this combination therapy for further investigation in clinical studies.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Ignacio Melero, Miguel F. Sanmamed, Javier Glez-Vaz, Carlos Luri-Rey, Jun Wang, Lieping Chen
Summary: Twenty-five years ago, it was discovered that agonist anti-CD137 monoclonal antibodies enhanced CD8+ T-cell antitumor immunity and effectively eradicated transplanted mouse tumors. Despite causing severe liver inflammation in some patients, the agonist antibody urelumab showed evidence of activity against melanoma and non-Hodgkin lymphoma. CD137's signaling domain has been incorporated into chimeric antigen receptors, improving their efficacy. New CD137 agonists, primarily based on bispecific constructs, are currently being tested in early-phase trials and are showing promising safety and clinical activity.
Article
Oncology
Seong-A Ju, Sang-Min Park, Yeonsoo Joe, Hun Chung, Won An, Byung-Sam Kim
Summary: This study aimed to improve the treatment strategies for incurable renal cell carcinoma (RCC). The combination therapy of immunostimulatory factor (ISTF) and anti-4-1BB monoclonal antibodies (mAbs) was established to enhance the antitumor response in a murine RCC model. The results showed that this combination therapy promoted partial tumor regression by increasing the number of activated effector cytotoxic T lymphocytes and IFN-gamma production.
Article
Medicine, Research & Experimental
Jiawei Chen, Songsong Zheng, Yongbin Hu, Xin Mou, Huiyang Wang
Summary: The study shows that chronic treatment with anti-GIPR mAb alone or in combination with DPP-4 inhibitor can improve body weight control, glucose metabolism, and pancreatic function in diabetic or DIO mice. The combined treatment exhibits a significantly improved weight loss compared to individual treatment, indicating a potential therapeutic approach for obesity. The study also highlights the important role of GIPR in regulating fat metabolism in pancreatic cells.
Article
Oncology
Alexandra L. Martin, Chase Powell, Mate Z. Nagy, Patrick Innamarato, John Powers, Derek Nichols, Carmen M. Anadon, Ricardo A. Chaurio, Sungjune Kim, Min-hsuan Wang, Bing Gong, Xianzhe Wang, Thomas J. Scheutz, Scott J. Antonia, Jose R. Conejo-Garcia, Bradford A. Perez
Summary: Radiation therapy (RT) can enhance systemic anti-tumor effects by activating STING and promoting tumor antigen presentation and recognition by T cells. This study shows that the accumulation of B and CD4(+) T cells at tumor beds induced by RT is necessary for inhibiting tumor growth in non-irradiated tumors. RT also increases the expression of 4-1BB in T and B cells, and combining RT with anti-4-1BB therapy enhances immune cell infiltration in the tumor microenvironment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Cell Biology
Dengli Wang, Daiki Ousaka, Handong Qiao, Ziyi Wang, Kun Zhao, Shangze Gao, Keyue Liu, Kiyoshi Teshigawara, Kenzo Takada, Masahiro Nishibori
Summary: This study found that humanized anti-HMGB1 mAb can inhibit the release of HMGB1, reduce the accumulation of 4-HNE and cerebral iron deposition, and decrease brain injury volume in the ICH model. In vitro experiments showed that recombinant HMGB1 delayed hemoglobin clearance, allowing the toxic effects of hemoglobin, heme, and Fe2 + to persist. Additionally, humanized anti-HMGB1 mAb reduced body weight loss and improved behavioral performance after ICH.
Article
Immunology
Ambily Anna Mathew, Zahara T. Zakkariya, Anusha Ashokan, Maneesh Manohar, Pavithran Keechilat, Shantikumar V. Nair, Manzoor Koyakutty
Summary: The researchers used various strategies to reverse the non-immunogenic character of the cold tumor, including photodynamic therapy, TAM repolarization, immune checkpoint inhibition, and MDSC depletion. Among them, low-dose 5-fluorouracil chemotherapy showed significant anti-tumor effects, primarily due to the increased infiltration of CD8+ cytotoxic T-cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Cai Zhao, Xiangshun Kong, Yao Rong, Weida Zheng, Peng Yu, Yuou Teng
Summary: In this study, a selenium substitute of axitinib was synthesized and its anti-renal cell carcinoma activity and side effects were investigated. The results showed that Se-axitinib had potent antitumor activity on renal cell carcinoma and alleviated the side effects of axitinib.
Article
Immunology
Ying Zhang, Xiaolong Wu, Amit Sharma, Hans Weiher, Matthias Schmid, Glen Kristiansen, Ingo G. H. Schmidt-Wolf
Summary: The study found that anti-CD40 antibody can increase the number of CD3+CD56+ effector cells in CIK cells by promoting the maturation and activation of dendritic cells. In addition, anti-CD40 antibody can also increase the expression of CTLA-4 in CIK cells. For the antitumor response of DC-CIK cells against renal cell carcinoma cells, anti-CD40 antibody is superior to anti-CTLA-4 antibody. The CTLA-4 inhibitor ipilimumab can significantly increase the proportion of CD3+CD56+ cells in DC-CIK cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Ying Wang, Kailun Zhong, Jun Ke, Xi Chen, Yi Chen, Wangyun Shu, Chunhuan Chen, Shan Hu, Xiaoke Sun, Haibin Huang, Chong Luo, Lifang Liu, Jiaming Yang, Yongke Zhang, Huijun Zhi
Summary: The authors designed a novel bicistronic CAR construct and demonstrated its enhanced anti-tumor efficacy in response to dual antigen stimulations. The bicistronic CAR T cells showed prolonged persistence and improved cytokine generation when stimulated with CD19 and CD20 simultaneously, making them more efficient in eradicating tumors and prolonging survival in a double-positive tumor model.
Article
Nanoscience & Nanotechnology
Xiaodong Wang, Chunyue Wang, Huimin Tian, Yichi Chen, Bolin Wu, Wen Cheng
Summary: This study investigated the combination therapy of sonodynamic therapy (SDT) and MG-132 for liver cancer and found that this combination treatment could effectively induce apoptosis and autophagy in HCC cells, thereby achieving anti-tumor therapy.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Review
Cell Biology
Daniele E. Mascarelli, Rhubia S. M. Rosa, Jessica M. Toscaro, Isadora F. Semionatto, Luciana P. Ruas, Carolinne T. Fogagnolo, Gabriel C. Lima, Marcio C. Bajgelman
Summary: Immunotherapy employs strategies to boost the host immune system's ability to detect and eliminate cancer cells, with costimulatory molecules playing a crucial role in the antitumor immune response.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Min Li, Mingyue Xia, Ziyu Zhang, Yanyin Tan, Enjie Li, Zhigang Guo, Mingzhi Fang, Yong Zhu, Zhigang Hu
Summary: This study reveals the important role of the METTL3/RAD51AP1 axis in the acquisition of 5-FU resistance in CRC, and targeting METTL3/RAD51AP1 may be a promising adjuvant therapeutic strategy for patients with CRC, particularly for those with 5-FU-resistant CRC.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Article
Oncology
Hee Yeon Kim, Jae-Hyeog Choi, Md Masudul Haque, Jin Hee Park, Il-Hwan Kim, Beom K. Choi, Anbok Lee, SaeGwang Park
Summary: Combination therapy with anti-4-1BB mAb and anti-HER2/neu mAb enhances the antitumor effect but does not induce immune memory. Immune memory can be maintained when anti-4-1BB mAb is administered to activated CD8(+) T cells.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa
Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.
INTERNATIONAL JOURNAL OF CANCER
(2024)
Correction
Oncology
J. Gu, S. Xie, S. Wang
INTERNATIONAL JOURNAL OF CANCER
(2024)